AIM ImmunoTech Inc. (AIM): who owns it and who trades it
As of Nov 13, 2026, AIM insiders reported 11 purchases worth $44.5K in the last 12 months. The largest buyer was Thomas K Equels (CEO), with $44.5K.
Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, AIM insiders reported $44.5K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Thomas K Equels | CEO | Purchase | 35,000 | $0.15 | $5.2K | Form 4 |
| Nov 10, 2026 | Thomas K Equels | CEO | Purchase | 39,000 | $0.14 | $5.4K | Form 4 |
| Nov 9, 2026 | Thomas K Equels | CEO | Purchase | 31,298 | $0.16 | $5.1K | Form 4 |
| Nov 6, 2026 | Thomas K Equels | CEO | Purchase | 12,751 | $0.16 | $2K | Form 4 |
| Nov 6, 2026 | Thomas K Equels | CEO | Purchase | 20,299 | $0.16 | $3.2K | Form 4 |
| Oct 23, 2026 | Thomas K Equels | CEO | Purchase | 31,675 | $0.16 | $5.1K | Form 4 |
| Oct 22, 2026 | Thomas K Equels | CEO | Purchase | 31,250 | $0.16 | $5.1K | Form 4 |
| Sep 17, 2026 | Thomas K Equels | CEO | Purchase | 24,000 | $0.21 | $5K | Form 4 |
| Sep 16, 2026 | Thomas K Equels | CEO | Purchase | 11,000 | $0.21 | $2.3K | Form 4 |
| Sep 15, 2026 | Thomas K Equels | CEO | Purchase | 22,000 | $0.22 | $4.8K | Form 4 |
| Sep 14, 2026 | Thomas K Equels | CEO | Purchase | 5,900 | $0.22 | $1.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Thomas K Equels | CEO & President, Director | $44.5K | – | Nov 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AIM short interest
Low short interest. 3.3% of AIM shares are sold short: about 1 share in 30. Over the last 12 reports the number of shares short went up 631%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.00M AIM shares were sold short, 3.3% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 406,598 shares, buying them all back would take about 2.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.00M | 3.29% | -7% | 406,598 | 2.5 |
| Oct 15, 2026 | 1.08M | 3.55% | -23% | 737,514 | 1.5 |
| Sep 30, 2026 | 1.41M | 4.62% | -49% | 1.87M | 1.0 |
| Sep 15, 2026 | 2.77M | 9.08% | +383% | 11.02M | 1.0 |
| Aug 31, 2026 | 572,582 | 1.88% | -17% | 12.14M | 1.0 |
| Aug 14, 2026 | 691,534 | 2.27% | -24% | 2.06M | 1.0 |
| Jul 31, 2026 | 913,892 | 11.22% | -41% | 741,607 | 1.2 |
| Jul 15, 2026 | 1.54M | 18.95% | -30% | 632,940 | 2.4 |
| Jun 30, 2026 | 2.20M | 27.02% | -31% | 2.32M | 1.0 |
| Jun 15, 2026 | 3.20M | 39.32% | -54% | 51.56M | 1.0 |
| May 29, 2026 | 7.01M | 86.08% | +5016% | 123.20M | 1.0 |
| May 15, 2026 | 137,078 | 1.68% | -55% | 1.56M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
AIM ImmunoTech company events
AIM ImmunoTech filed 25 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Sep 14, 2026AgreementFrom September 8, 2026 to September 9, 2026, AIM ImmunoTech Inc. entered into a total of two exchange agreements and, for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”) with Streeterville Capital, LLC related to that certain Promissory Note dated… Filing
- Sep 10, 2026AgreementOn September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. entered into a total of two exchange agreements and, for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”) with Streeterville Capital, LLC related to that certain Promissory Note dated… Filing
- Sep 4, 2026AgreementOn August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. entered into a total of five exchange agreements and, for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”) with Streeterville Capital, LLC related to that certain Promissory Note dated… Filing
- Aug 11, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementAIM ImmunoTech Inc. entered into a proposal with Sterling Pharma Solutions that is related to the Master Service Agreement and a Quality Agreement entered into between the Company and the Manufacturer in 2022. Filing
- Aug 5, 2026AgreementEnded an important agreement. Filing
- Jul 16, 2026VoteReported shareholder vote results. Filing
- Jun 15, 2026AnnouncementAIM ImmunoTech Inc. issued a press release announcing that on June 12, 2026, AIM received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of the NYSE American LLC. Filing
- Jun 11, 2026AgreementAIM ImmunoTech Inc. entered into a securities purchase agreement with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares of common stock, par value $0.001 per share, of the Company, at an offering price… Filing
- Jun 10, 2026RulesChanged its bylaws or articles. Filing
- Jun 4, 2026AnnouncementShared information with investors. Filing
- May 21, 2026AgreementAIM ImmunoTech Inc. entered into a securities purchase agreement with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 7,519,351 shares of common stock, par value $0.001 per share, of the Company, at an offering price… Filing
- May 19, 2026AgreementAs previously disclosed, AIM ImmunoTech Inc. previously issued to Streeterville Capital, LLC a Promissory Note in the original principal amount of $3.3 million dated February 16, 2024 pursuant to a Note Purchase Agreement between the Company and the Lender. Filing
- May 14, 2026AnnouncementShared information with investors. Filing
- May 12, 2026SharesSold new shares outside a public offering. Filing
- May 8, 2026AgreementAIM ImmunoTech Inc. entered into a warrant exercise inducement offer letter agreement with holders of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024, exercisable for up to an aggregate of 112,819 shares of the Company’s common stock, par value $0.001 per share, (ii)… Filing
- Apr 10, 2026AgreementAIM ImmunoTech Inc. entered into Amendment No. 1 to that certain Equity Distribution Agreement dated April 1, 2025 with Maxim Group LLC to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3 million of the Company’s shares of common stock, par value $0.001… Filing
- Mar 6, 2026AgreementIn connection with the closing of its previously announced Rights Offering (defined below), AIM ImmunoTech Inc. entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC, pursuant to which EQ agreed to act as warrant agent with respect to warrants included in the units issued by the… Filing
- Feb 5, 2026AnnouncementA Phase I/II Open Label Study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease Post-FOLFIRINOX is being conducted. Filing
- Jan 20, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 17, 2025VoteReported shareholder vote results. Filing
- Nov 19, 2025AgreementAIM ImmunoTech Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC and consummated the sale to such Investor of an unsecured Promissory Note with an original principal amount of $3.3 million in a private placement that closed on November 18, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
AIM ImmunoTech financials
Questions about AIM ImmunoTech Inc. (AIM) stock
Are AIM insiders buying or selling?
In the last 12 months, AIM insiders reported 11 open-market purchases worth $44.5K and no sales. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in AIM?
As of Oct 30, 2026, 1.00M AIM shares were sold short, 3.3% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 406,598 shares, buying them all back would take about 2.5 trading days (days to cover). See the history.
Executive pay
AIM ImmunoTech's chief executive was paid a total of $640K for the year ended Dec 31, 2025, down 41% from $1.1M the year before. In the last 12 months, AIM ImmunoTech's executives and directors bought $44.5K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.